Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

2.39
+0.15506.94%
Post-market: 2.580.1900+7.95%19:59 EDT
Volume:662.92K
Turnover:1.49M
Market Cap:3.90M
PE:-0.13
High:2.39
Open:2.25
Low:2.15
Close:2.24
52wk High:71.50
52wk Low:2.15
Shares:1.63M
Float Shares:1.22M
Volume Ratio:14.27
T/O Rate:54.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:1.22
PE(LYR):-0.04

Loading ...

Ernexa Says ERNA-101 Preclinical Data Win Flash Talk Slot at Nature-MD Anderson Cancer Meeting

Reuters
·
Oct 06

Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors

Reuters
·
Oct 01

Ernexa Therapeutics CEO Corner Highlights Appointment of DR. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances Erna-101 Toward the Clinic

THOMSON REUTERS
·
Oct 01

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

GlobeNewswire
·
Oct 01

Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101

TIPRANKS
·
Sep 30

Ernexa Targets Q4 2026 IND Filing for First-in-Human ERNA-101 Trial in Platinum-Resistant Ovarian Cancer

Reuters
·
Sep 30

Ernexa Therapeutics - no Teratoma Formation Observed in Erna-101-Treated Animals Through Six-Month Tumorigenicity Phase

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics Reports Compelling Erna-101 Safety Results Across Three Critical Ind-Enabling Studies, Advancing Toward Planned Q4 2026 Ind

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics - Biodistribution Study Shows no Significant Erna-101 Signal in Tumor-Free Animals or Non-Tumor Tissues

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics - Repeat-Dose Glp Toxicology Study Shows no Erna-101-Related Adverse Findings

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

GlobeNewswire
·
Sep 30

Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting

TIPRANKS
·
Sep 29

Ernexa Therapeutics CEO to Present at Cell & Gene Meeting on the Mesa Emerging Track

Reuters
·
Sep 29

Ernexa Therapeutics Director Robert J. Spiegel Files Initial Beneficial Ownership Statement

Reuters
·
Sep 23

Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors

Reuters
·
Sep 17

Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - Clinical Data from Erna-101 Proc Study Expected in Q4 2027

THOMSON REUTERS
·
Sep 15